Repligen Corporation (RGEN)
| Market Cap | 10.81B +28.0% |
| Revenue (ttm) | 805.61M +13.8% |
| Net Income | -11.80M |
| EPS | -0.21 |
| Shares Out | 63.92M |
| PE Ratio | n/a |
| Forward PE | 69.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 990,186 |
| Open | 175.60 |
| Previous Close | 178.20 |
| Day's Range | 168.03 - 176.66 |
| 52-Week Range | 100.99 - 198.87 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 203.45 (+20.28%) |
| Earnings Date | Oct 27, 2026 |
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $203.45, which is an increase of 20.28% from the latest price.
News
Repligen Corporation to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loei...
Repligen to issue $1B of 0.25% Convertible Senior Notes due 2031
Repligen (RGEN) announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 and certain ...
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements wit...
Repligen price target raised to $200 from $185 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Repligen (RGEN) to $200 from $185 and keeps an Outperform rating on the shares. The company’s Q3 results were…
Repligen Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $209 million with 12.5% organic growth, prompting higher FY2026 guidance. BioLife integration and record equipment orders support the 2027 outlook, though equipment delivery timing and market recovery remain key uncertainties.
Repligen Earnings release: Q3 2026
Repligen released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Repligen Slides: Q3 2026
Repligen has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Repligen Quarterly report: Q3 2026
Repligen has published its Q3 2026 quarterly earnings report on October 27, 2026.
Repligen reports Q3 adjusted EPS 53c, consensus 46c
Reports Q3 revenue $209.31M, consensus $206.75M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We delivered a record third quarter, with $209 million in revenue and...
Repligen narrows FY26 adjusted EPS view to $2.05-$2.09 from $2.03-$2.09
Consensus $2.06. Raises FY26 revenue view to $844M-$852M from $813M-$835M, consensus $836.29M. Loeillot continued, “The completion of the BioLife acquisition in October marks a significant milestone f...
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth ce...
Repligen price target raised to $180 from $145 at Canaccord
Canaccord raised the firm’s price target on Repligen (RGEN) to $180 from $145 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results.
Repligen to Report Third Quarter 2026 Financial Results
WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026...
Repligen price target raised to $225 from $175 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Repligen (RGEN) to $225 from $175 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Repligen Completes Acquisition of BioLife Solutions
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today annou...
Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8
Repligen (RGEN) is acquiring BioLife Solutions (BLFS) in a deal expected to be completed soon, pending final closing conditions.
Repligen Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong organic growth and upgraded guidance were driven by robust protein and analytics performance, while strategic acquisitions like BioLife Solutions are set to diversify the portfolio and accelerate margin expansion. Technology innovation, especially in AI and PAT, and regional gains in China/APAC support a positive outlook.
Repligen Slides: Wells Fargo 21st Annual Healthcare Conference
Repligen has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Repligen assumed with a Buy at UBS
UBS assumed coverage of Repligen (RGEN) with a Buy rating and $225 price target Repligen is a differentiated pure-play bioprocessing growth story with a path to sustained mid-teens revenue growth…
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...
Stifel sees Moderna data as positive for Repligen, Maravai
Stifel views Moderna’s (MRNA) Phase 3 INTerpath-001 data as good for Repligen (RGEN) and “conceptually good” for Maravai Lifesciences (MRVI). Repligen called out specific involvement in Moderna and Me...
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
Wells Fargo notes that Merck (MRK) and Moderna (MRNA) announced interim Phase 3 data for the latter’s personalized cancer vaccine, which hit their primary endpoint. While hard to quantify at…
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
Shares in Biopharma manufacturing company Repligen Corporation ($RGEN) raced 3% higher in early trading today after blockbuster results and a top analyst declaring it a market leader. Stellar Q2 Resul...
Repligen price target raised to $175 from $165 at JPMorgan
JPMorgan raised the firm’s price target on Repligen (RGEN) to $175 from $165 and keeps an Overweight rating on the shares.
